Skip to main content

Table 1 Clinical characteristics of patients with DR and BRVO

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

  DR BRVO p-value
Participants/Eyes (n) 146 142
Gender (male %) 52.0 48.0
Age (yrs) 55.34 ± 14.77 56.94 ± 19.28 0.497
BCVA (logMAR) (mean ± SD) 0.53 ± 0.21 0.55 ± 0.13 0.333
CME duration (m) 7.61 ± 8.13 5.77 ± 3.14 0.172
CFT (μm) 532.24 ± 76.33 545.55 ± 80.97 0.152
CME without SRF 69 (47.2%) 78 (54.9%) 0.240
CME with SRF 77 (52.7%) 64 (45.0%)
HEs area (mean ± SD) 0.61 ± 0.35 0.55 ± 0.58 0.287
HEs severity
 Absent 38 (26.0%) 41 (28.9%) 0.704
 Minimal (> 0–0.1 mm2) 44 (30.1%) 47 (33.1%) 0.719
 Mild (> 0.1–0.5 mm2) 33 (22.6%) 29 (20.4%) 0.780
 Moderate (> 0.5–2.5 mm2) 23 (15.8%) 18 (12.7%) 0.616
 Severe (> 2.5 mm2) 8 (5.5%) 7 (4.9%) 0.842
Laboratory data
 Total cholesterol (mmol/L) 4.41 ± 0.96 4.69 ± 0.88 0.231
 Triglyceride (mmol/L) 1.33 ± 0.48 1.36 ± 0.32 0.575
 LDL-C (mmol/L) 2.26 ± 0.21 2.19 ± 0.53 0.226
 HDL-C (mmol/L) 1.09 ± 0.17 1.15 ± 0.43 0.201
  1. BCVA Best correction vision acuity, BRVO Branch retinal vein occlusion, CFT Center foveal thickness, CME Cystoid macular edema, DR Diabetic retinopathy, HDL High-density lipoprotein. LDL Low-density lipoprotein. Data represent the mean ± SD of each group